Order expected to affect specific medications covered under Medicare that are administered in a health care setting.

SGLT2 inhibitors may enable continuation of RAAS inhibitors for hypertension treatment, which is linked with better kidney and cardiovascular outcomes.

Patients with DME who are treated using aflibercept are more likely to experience acute kidney injury or hospitalisation due to renal events than those treated with ranibizumab. Using a target ...